OmniAb Investor Conference Presentation Deck

Published Probability of Success and Timelines for Antibodies Discovery Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed Probability of Success (1) Cumulative from Program Start 100.0% 100.0% 51.0% 51.0% 69.0% 35.2% 54.7% 19.2% 34.1% 6.6% 68.1% 4.5% 95.4% 4.3% (1) Source: 2011-2020 Clinical Success Rates, BIO|QLS Advisors|Informa Feb 2021 Report Cumulative from Clinical Start 100.0% 54.7% 18.7% 12.7% 12.1% Time Range in Stage ~4 Years ~5 - 8 Years ~1 Year 29 OmniAb

View entire presentation